All In MedTech

FDA Clearance Tracker · P030035

ANTHEM AND FRONTIER II CRT-P'S

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: May 13, 2004 (this decision)Source: openFDAMethods & limitations

PMA

Decided

May 13, 2004

Approved

Time to decision

258 days

Received Aug 29, 2003. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P030035
Device name
ANTHEM AND FRONTIER II CRT-P'S
Applicant location
Sylmar, CA
Received
Aug 29, 2003
Decided
May 13, 2004
Decision
Approved
Supplements
202 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NKE

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE ST. JUDE FRONTIER BIVENTRICULAR CARDIAC PACING SYSTEM. THE FRONTIER BIVENTRICULAR PACING SYSTEM IS INDICATED FOR MAINTAINING SYNCHRONY OF THE LEFT AND RIGHT VENTRICLES IN PATIENTS WHO HAVE UNDERGONE AN AV NODAL ABLATION FOR CHRONIC ATRIAL FIBRILLATION AND HAVE NYHA CLASS II OR III HEART FAILURE.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NKE. The earliest in FDA's data is P030005, decided Jan 26, 2004.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.